{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:50:52Z","timestamp":1765371052047,"version":"3.46.0"},"reference-count":25,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inflamm Intest Dis"],"abstract":"<jats:p>&lt;p&gt;Introduction: Both mesalazine and ozanimod are oral treatment options for patients with moderately active ulcerative colitis (UC). Methods: Comparative analysis comparing efficacy endpoints of an 8-week non-inferiority induction study (TP0503) with 3.2 g\/day mesalazine (n = 321) to the True North 10-week induction study of 1 mg\/day ozanimod (n = 281). We compared the efficacy of oral mesalazine (Asacol) as monotherapy and ozanimod (Zeposia) as add-on therapy to mesalazine, without concomitant corticosteroids, following induction treatment in mesalazine-exposed but immunomodulator- and advanced therapy-na\u00efve UC patients. Endpoints from the non-inferiority study were re-calculated using the definitions from the True North study. Results: The two cohorts had similar age (45 \u00b1 14 years vs. 44 \u00b1 13.5 years) and baseline disease severity (total Mayo score; 8.5 \u00b1 0.8 vs. 8.6 \u00b1 1.1) for mesalazine- and ozanimod-treated patients, respectively. No differences were observed in patients achieving clinical response (reduction from baseline in the 3-component Mayo score [sum of rectal bleeding subscore\/RBS, stool frequency subscore\/SFS, and Mayo endoscopic score\/MES) of \u22652 points and \u226535%, and a reduction from baseline in the RBS of \u22651 point or an absolute RBS \u22641} (58% vs. 58%; p = 0.917) and clinical remission (RBS = 0, SFS \u22641 [and decreases of \u22651 point from baseline SFS], and MES \u22641) (22% vs. 28%; p = 0.074) treated with mesalazine (at 8 weeks) and ozanimod (at 10 weeks), respectively. A higher percentage of patients treated with ozanimod achieved endoscopic improvement (MES \u22641 without friability) compared to mesalazine (38% vs. 29%, p = 0.018). Conclusion: Among individuals previously exposed to mesalazine, a similar effect on clinical efficacy was observed between patients treated with mesalazine and those treated with ozanimod. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000548243","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:14:53Z","timestamp":1765358093000},"page":"337-346","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of Mesalazine and Ozanimod following Induction Treatment in Mesalazine-Exposed Advanced Therapy-Na\u00efve Adult Ulcerative Colitis Patients"],"prefix":"10.1159","volume":"10","author":[{"given":"Geert","family":"D&apos;Haens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Safroneeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6422-4623","authenticated-orcid":false,"given":"Helen","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00ebl","family":"Laoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.009"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000543.pub5"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000544.pub5"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/586092"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad112"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2011.172"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad106"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad009"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14164"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.06.068"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000531372"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00248.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.04.004"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.069"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000853"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04620.x"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(02)01383-9"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-13-23"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6632"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2012.011272"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2016-1012"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211041907"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.11.018"}],"container-title":["Inflammatory Intestinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000548243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:14:53Z","timestamp":1765358093000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000548243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000548243","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.30119173","asserted-by":"subject"}]},"ISSN":["2296-9403","2296-9365"],"issn-type":[{"value":"2296-9403","type":"print"},{"value":"2296-9365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}